BioSpace News Archive

Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE).

Previon has achieved ISO 13485 certification from NSF-ISR, an NSF company.

IASO Biotherapeutics (“IASO Bio”), and Innovent Biologics, Inc. (“Innovent,” HKEX: 01801), today jointly announced that the China National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Equecabtagene Autoleucel (IASO Bio R&D code: CT103A, Innovent R&D code: IBI326).

ProfoundBio announced the closing of a $70 million Series A+ financing round led by Sequoia China.

Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced today that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA).

Apnimed, today announced that data from a proof-of-concept study exploring two potential oral therapeutic candidates for the treatment of patients with OSA, AD504 (atomoxetine + trazodone) and AD182, will be featured in an oral presentation at SLEEP 2022 in Charlotte, NC, on Monday, June 6.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 5,500 shares of Astria’s common stock on June 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.

Completed pharmacokinetic study of ANJ900 in healthy Chinese volunteers.

Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED).